Regeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage Trial

By Kimberly Chin

Regeneron Pharmaceuticals Inc. said that its eye-injection treatment for patients with wet age-related macular degeneration, a kind of eye disorder, met the primary endpoint in a Phase 2 trial.

The biotechnology company said an 8 mg aflibercept injection over an extended period of time showed numeric improvements in anatomical and vision outcomes compared with a lower dose of the currently-approved Eylea.

Regeneron previously said that patients that received the treatment had no retinal fluid in the macula after the 16th week, when the primary-efficacy endpoint was being assessed.

After the 16th week, the company started administering doses every 12 weeks.

"This is the first time we have seen a promising trend towards sustained improved vision over Eylea in wet AMD," David Brown, the director of research at Retina Consultants of Texas said.

The company said it will present its findings at an annual Angiogenesis meeting on Saturday.

Regeneron expects results from a Phase 3 trial in wet age-related macular degeneration and diabetic macular edema in the second half of the year.

Write to Kimberly Chin at [e-mail]

(END) Dow Jones Newswires

February 11, 2022 08:36 ET (13:36 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.